Medicare to Lower Costs for Weight-Loss Drugs

Millions of Medicare recipients may soon experience a significant reduction in the cost of popular weight-loss drugs, with some paying about $50 monthly under a new federal initiative. The Medicare GLP-1 Bridge program, launching on July 1, aims to broaden access to a highly sought-after class of medications, historically unaffordable for many seniors.

Why This Change Matters

This initiative represents a major change in Medicare drug access. Previously, federal regulations prevented Medicare from covering weight-loss medications. GLP-1 drugs have gained popularity due to their effectiveness in promoting significant weight loss and lowering risks of chronic diseases like heart disease. Despite these health benefits, their high cost, often exceeding $900 per month without insurance, limited access for seniors on fixed incomes. By capping out-of-pocket costs at $50 per month, federal officials aim to make these treatments accessible to millions of older Americans.

Details You Need to Know

Starting July 1, eligible Medicare beneficiaries with prescription drug coverage can access certain GLP-1 medications for about $50 a month. The temporary ‘bridge’ program, managed by the Centers for Medicare & Medicaid Services (CMS), will run until December 31, 2027.

CMS Administrator Dr. Mehmet Oz stated, “These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost. The Medicare GLP-1 Bridge changes that by making these medications more affordable and accessible.”

GLP-1 medications, such as Wegovy, Foundayo, and Zepbound, were initially developed to treat Type 2 diabetes but are now commonly prescribed for weight loss. Experts highlight that the program’s structure places it outside regular Medicare channels, testing the feasibility of obesity medications for a broad participant base. Alex Beene from the University of Tennessee at Martin noted that the program’s future beyond 2027 would require reintegration into existing Medicare services or further revisions.

Eligibility Criteria

• Enrollment in a Medicare Part D or Medicare Advantage drug plan
• A doctor’s prescription and prior authorization
• Medical criteria, like obesity or related conditions

Eligible patients must coordinate with healthcare providers, who will submit necessary clinical documentation through a centralized CMS system.

Medications in the Medicare GLP-1 Bridge Program

Part D plan members eligible for the Medicare GLP-1 Bridge program will gain access to:

• Foundayo
• Wegovy (injection or tablet)
• Zepbound (KwikPen)

How the Pricing Works

The program operates outside traditional Part D rules, offering a flat $50 monthly copay for a 30-day supply. This fee will not contribute to a beneficiary’s deductible or annual out-of-pocket maximum. Kevin Thompson of 9i Capital Group cautioned about questions regarding who will bear the financial burden in the long term. Although treatments may require extended use, the sustainability post-2027 remains uncertain.

Taking Action for Medicare Beneficiaries

If you receive Medicare, consider the following steps:

• Check eligibility: Discuss with your doctor if you qualify.
• Confirm drug coverage: Not all GLP-1 medications may be covered.
• Prepare for July 1: The program starts nationwide then.

Looking Ahead

The GLP-1 Bridge is designed to inform future CMS policy decisions. Without an extension beyond 2027, patient access could end, potentially undoing health improvements made during the program. Alex Beene raised concerns about the potential resurgence of weight-management issues if the program lapses.